The HTAi Annual Meeting 2017 will be held in Rome, Italy, 17-21st June 2017. The theme of the meeting is Towards an HTA Ecosystem: From Local Needs to Global Opportunities. Several members of the OHE team will attend and participate in the conference.
Just published is a new book entitled “Multi-criteria Decision Analysis (MCDA) to Support Healthcare Decisions”. It features a chapter by OHE’s Martina Garau and Professor Nancy Devlin on opportunities and challenges of MCDA in HTA.
There are three EQ-5D value sets available for use in cost effectiveness analysis in the UK and/or England:
- the UK EQ-5D-3L value set (often called the ‘MVH’ value set) which has been used for two decades, e.g. in evidence submitted to NICE (Dolan, 1997);
- a ‘crosswalk’ value set (van Hout et al., 2012), which maps patients’ EQ-5D-5L data to the EQ-5D-3L descriptive system, so that the MVH value set can be applied; and
- the EQ-5D-5L value set for England (Devlin et al., 2016).
How do these value sets differ? And how important are these differences likely to be for users?
A new OHE Research Paper by Mulhern et al. (2017) compares the characteristics of the value sets.
Just published is a new OHE Consulting Report entitled: Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose? The purpose of the new OHE report is to explore a review exercise undertaken by NICE and the University of York and to assess whether or not the resulting conclusions are appropriate.
A new OHE Research Paper assesses the nature of evidence used to reach HTA decisions which NICE have classified as “Recommended in Line with Clinical Practice” between 2007 and mid-2016. The level of patient access associated with these decisions has also been assessed.